CTLA-4 inhibitors are monoclonal antibodies designed to block the interaction between CTLA-4 and its ligands. This blockade lifts the brakes on the immune system, allowing T cells to become more active against cancer cells. Ipilimumab is one of the most well-known CTLA-4 inhibitors and has been approved for the treatment of various cancers, including melanoma.
